These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 28367235)

  • 1. Combined Targeting of mTOR and Akt Using Rapamycin and MK-2206 in The Treatment of Tuberous Sclerosis Complex.
    Ji S; Lin W; Wang L; Ni Z; Jin F; Zha X; Fei G
    J Cancer; 2017; 8(4):555-562. PubMed ID: 28367235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.
    Wang Y; Tang S; Wu Y; Wan X; Zhou M; Li H; Zha X
    IUBMB Life; 2020 May; 72(5):965-977. PubMed ID: 31958214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deficient TSC1/TSC2-complex suppression of SOX9-osteopontin-AKT signalling cascade constrains tumour growth in tuberous sclerosis complex.
    Jin F; Jiang K; Ji S; Wang L; Ni Z; Huang F; Li C; Chen R; Zhang H; Hu Z; Zha X
    Hum Mol Genet; 2017 Jan; 26(2):407-419. PubMed ID: 28013293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperactivated mTORC1 downregulation of FOXO3a/PDGFRα/AKT cascade restrains tuberous sclerosis complex-associated tumor development.
    Wang L; Ni Z; Liu Y; Ji S; Jin F; Jiang K; Ma J; Ren C; Zhang H; Hu Z; Zha X
    Oncotarget; 2017 Aug; 8(33):54858-54872. PubMed ID: 28903387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTORC1-mediated downregulation of COX2 restrains tumor growth caused by TSC2 deficiency.
    Li H; Jin F; Jiang K; Ji S; Wang L; Ni Z; Chen X; Hu Z; Zhang H; Liu Y; Qin Y; Zha X
    Oncotarget; 2016 May; 7(19):28435-47. PubMed ID: 27078846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor suppressors TSC1 and TSC2 differentially modulate actin cytoskeleton and motility of mouse embryonic fibroblasts.
    Goncharova EA; James ML; Kudryashova TV; Goncharov DA; Krymskaya VP
    PLoS One; 2014; 9(10):e111476. PubMed ID: 25360538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
    Mi R; Ma J; Zhang D; Li L; Zhang H
    J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
    Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
    PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycin-insensitive and polycystin 1-independent pathway.
    Hartman TR; Liu D; Zilfou JT; Robb V; Morrison T; Watnick T; Henske EP
    Hum Mol Genet; 2009 Jan; 18(1):151-63. PubMed ID: 18845692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin.
    El-Hashemite N; Walker V; Zhang H; Kwiatkowski DJ
    Cancer Res; 2003 Sep; 63(17):5173-7. PubMed ID: 14500340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapamycin requires AMPK activity and p27 expression for promoting autophagy-dependent Tsc2-null cell survival.
    Campos T; Ziehe J; Fuentes-Villalobos F; Riquelme O; Peña D; Troncoso R; Lavandero S; Morin V; Pincheira R; Castro AF
    Biochim Biophys Acta; 2016 Jun; 1863(6 Pt A):1200-7. PubMed ID: 26975583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neural progenitors derived from Tuberous Sclerosis Complex patients exhibit attenuated PI3K/AKT signaling and delayed neuronal differentiation.
    Zucco AJ; Pozzo VD; Afinogenova A; Hart RP; Devinsky O; D'Arcangelo G
    Mol Cell Neurosci; 2018 Oct; 92():149-163. PubMed ID: 30144504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779.
    Messina MP; Rauktys A; Lee L; Dabora SL
    BMC Pharmacol; 2007 Nov; 7():14. PubMed ID: 17986349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterozygosity for the tuberous sclerosis complex (TSC) gene products results in increased astrocyte numbers and decreased p27-Kip1 expression in TSC2+/- cells.
    Uhlmann EJ; Apicelli AJ; Baldwin RL; Burke SP; Bajenaru ML; Onda H; Kwiatkowski D; Gutmann DH
    Oncogene; 2002 Jun; 21(25):4050-9. PubMed ID: 12037687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Missense mutations to the TSC1 gene cause tuberous sclerosis complex.
    Nellist M; van den Heuvel D; Schluep D; Exalto C; Goedbloed M; Maat-Kievit A; van Essen T; van Spaendonck-Zwarts K; Jansen F; Helderman P; Bartalini G; Vierimaa O; Penttinen M; van den Ende J; van den Ouweland A; Halley D
    Eur J Hum Genet; 2009 Mar; 17(3):319-28. PubMed ID: 18830229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A brain proteomic investigation of rapamycin effects in the
    Wesseling H; Elgersma Y; Bahn S
    Mol Autism; 2017; 8():41. PubMed ID: 28775826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Dual Inhibition of Glycolysis and Glutaminolysis for Therapy of Renal Lesions in Tsc2
    Jones AT; Narov K; Yang J; Sampson JR; Shen MH
    Neoplasia; 2019 Feb; 21(2):230-238. PubMed ID: 30622053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways.
    Kwiatkowski DJ; Manning BD
    Hum Mol Genet; 2005 Oct; 14 Spec No. 2():R251-8. PubMed ID: 16244323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormal glycogen storage in tuberous sclerosis complex caused by impairment of mTORC1-dependent and -independent signaling pathways.
    Pal R; Xiong Y; Sardiello M
    Proc Natl Acad Sci U S A; 2019 Feb; 116(8):2977-2986. PubMed ID: 30728291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR.
    Zhang H; Bajraszewski N; Wu E; Wang H; Moseman AP; Dabora SL; Griffin JD; Kwiatkowski DJ
    J Clin Invest; 2007 Mar; 117(3):730-8. PubMed ID: 17290308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.